Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial

JAMA

Volumn 302, Issue 23, 2009, Pages 2557-2564

  Green, Robert C ^a   Schneider, Lon S ^b   Amato, David A ^c   Beelen, Andrew P ^c   Wilcock, Gordon ^d   Swabb, Edward A ^c   Zavitz, Kenton H ^c  

^a BOSTON UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Myriad Pharmaceuticals   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CENTRAL STIMULANT AGENT; CHOLINESTERASE INHIBITOR; MEMANTINE; PLACEBO; TARENFLURBIL; VITAMIN;

ADULT; AGED; ALZHEIMER DISEASE; ANEMIA; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIGESTIVE SYSTEM ULCER; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EOSINOPHIL COUNT; EOSINOPHILIA; FEMALE; HERPES ZOSTER; HUMAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STROKE; UPPER RESPIRATORY TRACT INFECTION;

EID: 72549105935     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.1866     Document Type: Article

References (30)

1. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184-185.
2. 184-185. 2. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81(2):741-766. (Pubitemid 32267077)
3. McGowan E, Pickford F, Kim J, et al. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005;47(2):191-199. (Pubitemid 41019251)
4. Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest. 2003; 112(3):440-449.
5. Kukar TL, Ladd TB, Bann MA, et al. Substratetargeting gamma-secretase modulators. Nature. 2008; 453(7197):925-929.
6. Kukar T, Prescott S, Eriksen JL, et al. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci. 2007;8:54-66.
7. Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA; Tarenflurbil Phase II Study investigators. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol. 2008;7(6): 483-493.
8. McKhann G, Drachman D, Folstein MF, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease. Neurology. 1984;34(7):939-944.
9. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathologic verification of ischemic score in differentiation of dementias. Ann Neurol. 1980;7(5): 486-488.
10. Rosen W, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984; 141(11):1356-1364. (Pubitemid 14023930)
11. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S33-S39. (Pubitemid 27303108)
12. Morris JC. The Clinical Dementia Rating (CDR). Neurology. 1993;43(11):2412-2414.
13. Folstein MF, Folstein SE, McHugh PR. "Mini- Mental State." J Psychiatr Res. 1975;12(3):189-198.
14. Cummings JL. The neuropsychiatric inventory. Neurology. 1997;48(5)(suppl 6):S10-S16.
15. Logsdon RG, Gibbons LE, McCurry SM, et al. Quality of life in Alzheimer's disease. J Ment Health Aging. 1999;5:21-32.
16. Novak M, Guest C. Application of a multidimensional caregiver burden inventory. Gerontologist. 1989; 29(6):798-803. (Pubitemid 20082601)
17. Tracy TS, Rosenbluth BW, Wrighton SA, Gonzalez FJ, Korzekwa KR. Role of cytochrome P450 2C9 and an allelic variant of the 4'-hydroxylation of (R)- and (S)-flurbiprofen. Bioch Pharm. 2005;49(9):1269-11127
18. Galasko DR, Graff-Radford N, May S, et al. Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord. 2007; 21(4):292-299. (Pubitemid 350307433)
19. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidgenic Abeta42 independently of cyclooxygenase activity. Nature. 2001;414(6860): 212-216. (Pubitemid 33051236)
20. Lim G, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci. 2000; 20(15):5709-5714. (Pubitemid 30636898)
21. Yan Q, Zhang J, Liu H, et al. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci. 2003;23(20):7504-7509. (Pubitemid 37034066)
22. Jantzen PI, Connor K, DiCarlo G, et al. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal antiinflammatory drug in amyloid precurser protein plus presenilin-1 transgenic mice. J Neurosci. 2002; 22(6):2246-2254. (Pubitemid 35386524)
23. Yao Y, Chinnici C, Tang H. Brain inflammation and oxidative stress in a transgenic mouse model of Alzheimer- like brain amyloidosis. J Neuroinflammation. 2004;1:1-21.
24. Brune K, Geisslinger G, Menzel-Soglowek S. Pure enantiomers of 2-arylproprionic acids. J Clin Pharmacol. 1992;32(10):944-952.
25. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex and ethnicity on the association between apolipoprotein E genotype and Alzheimer's Disease: A meta-analysis. JAMA. 1997;278(16):1349-1356.
26. Aisen PS, Schneider LS, Sano M, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease. JAMA. 2008;300(15):1774-1783.
27. Gauthier S, Douillet P,Doody R, Fox NC,Orgogozo JM. Effect of xaliproden, a compound with neurotrophic properties, on the progression of Alzheimer's disease. Presentation and poster at: Clinical Trials in Alzheimer Disease: September 17-19, 2008; Montpellier, France.
28. Sano M. Multi-center, randomized, doubleblind, placebo controlled trial of Simvastatin to slow the progression of Alzheimer's disease. Alzheimers Dement. 2008;4:T200.
29. PhRMA Web Synopsis: protocol A2581078 01 June 2008 Final. http://www.clinicalstudyresults.org /documents/company-study-4374-0.pdf. Accessed April 15, 2009.
30. Schneider LS, Sano M. Current Alzheimer's disease clinical trials. Alzheimers Dement. 2009; 5(5):388-397.